Maria Rosa Costanzo, MD
Advanced Heart Failure and Transplant Cardiology · Naperville, ILNPI 1073564860
Payments from drug & device makers
Across 481 payments — averaging $3264.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$599K
- Nuwellis, Inc.$369K
- Boehringer Ingelheim International GmbH$228K
- Novartis$142K
- Bayer$39K
- Merck$32K
- plus $160K from 20 others
Across 2 payments — averaging $51.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$103
What the payments were for
- Consulting fees$220,82931%
- Speaking & faculty fees$378,90453%
- Travel & lodging$53,8848%
- Food & beverage$62,5369%
- Education$40%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 150 | $599,166 |
| Nuwellis, Inc. | 57 | $368,982 |
| Boehringer Ingelheim International GmbH | 129 | $228,469 |
| Novartis | 17 | $142,084 |
| Bayer | 21 | $38,946 |
| Merck | 14 | $32,277 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 7 | $30,497 |
| Actelion Pharmaceuticals, Ltd | 9 | $19,650 |
| Fresenius USA Marketing, Inc. | 7 | $19,484 |
| Eli Lilly | 7 | $18,600 |
| ZOLL Respicardia, Inc. | 4 | $15,188 |
| Boehringer Ingelheim | 7 | $12,445 |
| Nxstage Medical, Inc. | 11 | $9,628 |
| Scpharmaceuticals Inc. | 3 | $8,953 |
| Boehringer Ingelheim (phil.) Inc. | 1 | $5,600 |
| Boston Scientific | 8 | $4,697 |
| Vifor Pharma, Inc. | 7 | $4,263 |
| Boehringer Ingelheim Mexico SA De CV | 1 | $3,600 |
| E.r. Squibb & Sons, L.L.C. | 5 | $3,068 |
| AstraZeneca | 4 | $2,539 |
| Cvrx, Inc. | 3 | $1,018 |
| Medtronic | 1 | $563 |
| United Therapeutics Corporation | 4 | $271 |
| Impulse Dynamics (USA) Inc. | 1 | $182 |
| Outset Medical Inc | 1 | $71 |
| Amgen | 2 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AQUADEX SMARTFLOW CONSOLE$306,921
- JARDIANCE$191,531
- Aquadex$61,758
- CardioMEMS HF System$25,937
- remede System$15,188
- FUROSCIX$8,953
- System One$6,488
- VERQUVO$5,000
- GENERAL - THERAPIES$4,425
- Mitra Clip system$4,205
- Veltassa$4,150
- CARDIOMEMS$3,750
- NXSTAGE SYSTEM ONE$3,000
- FARXIGA$2,417
- OPTIMIZER$365
- Barostim Neo System$268
- HeartMate 3 Left Ventricular Dev$180
- HeartMate II LVAS$179
- ORENITRAM$127
- REMODULIN$127
How this compares
$1,570,276 in reported general payments places this provider in the 95th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.
See all advanced heart failure and transplant cardiology providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 265 | $427,505 |
| JardianceEmpagliflozin | 234 | $348,188 |
| VyndamaxTafamidis | 11 | $256,202 |
| UptraviSelexipag | 11 | $239,647 |
| OpsumitMacitentan | 18 | $228,833 |
| FarxigaDapagliflozin Propanediol | 116 | $132,484 |
| Ambrisentan | 18 | $114,012 |
| EliquisApixaban | 76 | $78,251 |
| XareltoRivaroxaban | 43 | $41,870 |
| Repatha SureclickEvolocumab | 37 | $36,369 |
| Eplerenone | 183 | $12,746 |
| Metoprolol Succinate | 398 | $6,981 |
| Tacrolimus | 24 | $5,192 |
| Ranolazine ErRanolazine | 11 | $3,899 |
| Carvedilol ErCarvedilol Phosphate | 11 | $3,651 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $142,084 | $427,505265 claims |
| Boehringer IngelheimJardiance | $12,445 | $348,188234 claims |
| AstraZenecaFarxiga | $2,539 | $132,484116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.
Other advanced heart failure and transplant cardiology in Naperville
- Ron OrenNaperville$50K
- Stanislaw SkalubaNaperville$41K
- Deep ShahNaperville$8K
- Ali ValikaElmhurst$851K
- Manreet KanwarChicago$477K
- Jonathan RichChicago$373K
- Chetan BhardwajPeoria$348K
- Yasmin RazaChicago$319K
- Jane WilcoxChicago$284K
- Michele MontpetitWinfield$269K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.